Body Mass Index and Comorbidities in Adult Severe Asthmatics

Table 1

Demographic characteristics of patients.

	Normal weight; (BMI<25)	Overweight; (25.0≤BMI<30.0)	Obese; (BMI≥30)	𝑃 value
No.	42	36	24
Body mass index (median and IQR)	22.7 (20.6–23.7)	27.5 (26.4–28.6)	32.3 (30.8–35.3)	< 𝟎.𝟎𝟎𝟎𝟏^∗
Age (yrs, mean ± SD)	56.6±15.1	58.8±12.1	53.2±14.6	0.32**
Gender (males, %)	35.4	61.1	33.3	𝟎.𝟎𝟑𝟖^∗∗∗
Optimal asthma control (%)	71.4	28.6	0.0	𝟎.𝟎𝟐𝟑^∗∗∗
Mean ACQ score (median and IQR)	2.4 (1.3–3.3)	2.0 (1.1–3.3)	3.3 (3.0–3.7)	𝟎.𝟎𝟎𝟓^∗
No. of exacerbation in the last year (median and IQR)	2 (1–3)	2 (1–3)	3 (2–5)	𝟎.𝟎𝟓𝟐^∗
FEV1 (% of predicted, mean ± SD)	64.8±16.8	63.3±17.3	55.7±14.9	0.09**
FVC (% of predicted, mean ± SD)	69.7±15.7	68.2±16.5	60.6±11.6	0.06**
FEV1/FVC (absolute %, mean ± SD)	73.3±4.4	72.5±4.7	72.7±9.5	0.85**
Asthma duration (yrs, median and IQR)	27.5 (21.0–37.0)	26.0 (10.0–37.5)	26.5 (19.0–40.0)	0.69*
Hospitalization for asthma ever (%)	81.0	8.33	75.0	0.72***
Intensive Care Unit for asthma ever (%)	28.6	27.8	33.3	0.89***
OCS in the previous year for asthma (%)	50.0	72.2	79.2	𝟎.𝟎𝟐𝟗^∗∗∗
LABA use in the previous year (%)	69.0	83.3	95.8	𝟎.𝟎𝟐𝟕^∗∗∗
Aspirine intolerance (%)	14.3	13.9	4.2	0.42***
Antidepressant use (%)	7.1	8.3	4.2	0.82***
Antisthaminic use (%)	64.3	52.8	75.0	0.21***

IQR: interquartile range; ACQ: Asthma Control Questionnaire, Juniper scores; OCS: oral corticosteroids; LABA: long-acting 𝛽₂-agonists.
Statistical significance among groups was evaluated by *Kruskall-Wallis test, **analysis of variance, and ***𝜒² test.